Calcium electroporation for recurrent head and neck cancer: A clinical phase I study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Calcium electroporation for recurrent head and neck cancer : A clinical phase I study. / Plaschke, Christina Caroline; Gehl, Julie; Johannesen, Helle Hjorth; Fischer, Barbara Malene; Kjaer, Andreas; Lomholt, Anne Fog; Wessel, Irene.
I: Laryngoscope investigative otolaryngology, Bind 4, Nr. 1, 02.2019, s. 49-56.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Calcium electroporation for recurrent head and neck cancer
T2 - A clinical phase I study
AU - Plaschke, Christina Caroline
AU - Gehl, Julie
AU - Johannesen, Helle Hjorth
AU - Fischer, Barbara Malene
AU - Kjaer, Andreas
AU - Lomholt, Anne Fog
AU - Wessel, Irene
PY - 2019/2
Y1 - 2019/2
N2 - Background: Calcium electroporation is a novel cancer treatment, which combines temporary cell permeability from electroporation with a high influx of calcium intracellularly resulting in cancer cell necrosis.Methods: A phase I trial performing calcium electroporation on 6 patients suffering from recurrent head and neck cancer. In general anesthesia, intratumoral calcium injections were followed by electroporation. Safety was monitored by adverse events registration, serum Ca2+, ECG, and pain scores. Tumor response was measured on PET/MRI scans.Results: Procedures were performed without complications. No serious adverse events, signs of hypercalcemia, or cardiac arrhythmias were observed. Two months post-treatment tumor responses on MRI: three partial responses, one stable disease, and two progression. Responses on PET: one partial metabolic disease, four with stable metabolic disease, and one not evaluable. One patient was without clinical evidence of disease after 12 months of observation.Conclusion: Calcium electroporation is feasible and safe in head and neck tumors. Clinical responses were observed in three of six patients, warranting further studies.Level of Evidence: Level 4.
AB - Background: Calcium electroporation is a novel cancer treatment, which combines temporary cell permeability from electroporation with a high influx of calcium intracellularly resulting in cancer cell necrosis.Methods: A phase I trial performing calcium electroporation on 6 patients suffering from recurrent head and neck cancer. In general anesthesia, intratumoral calcium injections were followed by electroporation. Safety was monitored by adverse events registration, serum Ca2+, ECG, and pain scores. Tumor response was measured on PET/MRI scans.Results: Procedures were performed without complications. No serious adverse events, signs of hypercalcemia, or cardiac arrhythmias were observed. Two months post-treatment tumor responses on MRI: three partial responses, one stable disease, and two progression. Responses on PET: one partial metabolic disease, four with stable metabolic disease, and one not evaluable. One patient was without clinical evidence of disease after 12 months of observation.Conclusion: Calcium electroporation is feasible and safe in head and neck tumors. Clinical responses were observed in three of six patients, warranting further studies.Level of Evidence: Level 4.
U2 - 10.1002/lio2.233
DO - 10.1002/lio2.233
M3 - Journal article
C2 - 30828619
VL - 4
SP - 49
EP - 56
JO - Laryngoscope investigative otolaryngology
JF - Laryngoscope investigative otolaryngology
SN - 2378-8039
IS - 1
ER -
ID: 236271120